Results 211 to 220 of about 61,539 (257)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 1987
Hairy cell leukemia is a chronic lymphoproliferative disorder that has been recognized as a separate clinical pathologic entity for the last 25 years. After a decade of discussions about the origin of the neoplastic cell, it has now been well established that hairy cells represent a certain, rather mature stage of B-cell differentiation.
Jan Jansen, L.T. Yam
openaire +4 more sources
Hairy cell leukemia is a chronic lymphoproliferative disorder that has been recognized as a separate clinical pathologic entity for the last 25 years. After a decade of discussions about the origin of the neoplastic cell, it has now been well established that hairy cells represent a certain, rather mature stage of B-cell differentiation.
Jan Jansen, L.T. Yam
openaire +4 more sources
Recenti progressi in medicina, 1979
Hairy cell leukemia, or leukemic reticuloendotheliosis, is a chronic leu kemia that has received increased attention in recent years. Much of the current vogue in the recognition of this disease may be due to the employ ment of the term "hairy cell," first used by Schrek & Donnelly (1) to describe the villous cytoplasmic projections of the leukemic ...
Carbone A +5 more
openaire +6 more sources
Hairy cell leukemia, or leukemic reticuloendotheliosis, is a chronic leu kemia that has received increased attention in recent years. Much of the current vogue in the recognition of this disease may be due to the employ ment of the term "hairy cell," first used by Schrek & Donnelly (1) to describe the villous cytoplasmic projections of the leukemic ...
Carbone A +5 more
openaire +6 more sources
Current Treatment Options in Oncology, 2001
The standard therapy for hairy cell leukemia (HCL) is with the nucleoside analogs, 2"-deoxycoformycin (dCF) or 2-chlorodeoxyadenosine (CdA), which produce morphologic complete remissions (CRs) in the majority of patients, although residual hairy cells can frequently be detected by molecular or immunologic techniques.
L, Savoie, J B, Johnston
openaire +2 more sources
The standard therapy for hairy cell leukemia (HCL) is with the nucleoside analogs, 2"-deoxycoformycin (dCF) or 2-chlorodeoxyadenosine (CdA), which produce morphologic complete remissions (CRs) in the majority of patients, although residual hairy cells can frequently be detected by molecular or immunologic techniques.
L, Savoie, J B, Johnston
openaire +2 more sources
Current Oncology Reports, 2020
To summarise diagnostic clinical/laboratory findings and highlight differences between classical hairy cell leukaemia (HCLc) and hairy cell leukaemia variant (HCLv). Discussion of prognosis and current treatment indications including novel therapies, linked to understanding of the underlying molecular pathogenesis.Improved understanding of the ...
Matthew, Cross, Claire, Dearden
openaire +2 more sources
To summarise diagnostic clinical/laboratory findings and highlight differences between classical hairy cell leukaemia (HCLc) and hairy cell leukaemia variant (HCLv). Discussion of prognosis and current treatment indications including novel therapies, linked to understanding of the underlying molecular pathogenesis.Improved understanding of the ...
Matthew, Cross, Claire, Dearden
openaire +2 more sources
Current Oncology Reports, 2006
Hairy cell leukemia is a rare B-cell neoplasm. When treated with either pentostatin or cladribine, complete and durable remissions can be secured and life expectancy for most patients is normal. A small minority of patients require alternative treatment with monoclonal antibodies or immunotoxins.
Claire, Dearden, Monica, Else
openaire +2 more sources
Hairy cell leukemia is a rare B-cell neoplasm. When treated with either pentostatin or cladribine, complete and durable remissions can be secured and life expectancy for most patients is normal. A small minority of patients require alternative treatment with monoclonal antibodies or immunotoxins.
Claire, Dearden, Monica, Else
openaire +2 more sources
Current Problems in Cancer, 1984
Hairy cell leukemia is a malignancy with a variable course that can be relatively indolent or rapidly fatal. Alterations in the immune system are responsible for much of the morbidity and mortality from hairy cell leukemia. More than 60% of patients die from infection, and infections are both pyogenic and nonpyogenic.
M K, Offermann, H M, Golomb
openaire +4 more sources
Hairy cell leukemia is a malignancy with a variable course that can be relatively indolent or rapidly fatal. Alterations in the immune system are responsible for much of the morbidity and mortality from hairy cell leukemia. More than 60% of patients die from infection, and infections are both pyogenic and nonpyogenic.
M K, Offermann, H M, Golomb
openaire +4 more sources
Best Practice & Research Clinical Haematology, 2003
The evidence that hairy cells are activated clonal late B cells is presented. The largely non-specific (i.e. not confined to hairy-cell leukaemia) chromosome and genetic abnormalities are then described. Next, the features of malignant-cell activation are considered, including the distinctive morphology of hairy cells and their expression of activation-
M, Zuzel, J C, Cawley
openaire +2 more sources
The evidence that hairy cells are activated clonal late B cells is presented. The largely non-specific (i.e. not confined to hairy-cell leukaemia) chromosome and genetic abnormalities are then described. Next, the features of malignant-cell activation are considered, including the distinctive morphology of hairy cells and their expression of activation-
M, Zuzel, J C, Cawley
openaire +2 more sources
Blood, 2014
![Figure][1] A 49-year-old man presented with a history of weakness lasting one year. Physical findings included pallor and a 12-cm palpable spleen. Complete blood counts reported hemoglobin 8.0 g/L, hematocrit 26.6, mean corpuscular volume 92 fL, mean corpuscular hemoglobin 27.8 pg ...
Bushra, Moiz, Hira, Qadir
openaire +2 more sources
![Figure][1] A 49-year-old man presented with a history of weakness lasting one year. Physical findings included pallor and a 12-cm palpable spleen. Complete blood counts reported hemoglobin 8.0 g/L, hematocrit 26.6, mean corpuscular volume 92 fL, mean corpuscular hemoglobin 27.8 pg ...
Bushra, Moiz, Hira, Qadir
openaire +2 more sources
The Pathophysiology of the Hairy Cell
Hematology/Oncology Clinics of North America, 2006HCs are clonal late B cells that are related to memory cells and display specific features of activation. Many of the distinctive features of HCs (eg, morphology, TRAP) are related to this specific activation. Many of the distinctive histologic features of HCL can be related to constitutive production of cytokines (eg, FGF, fibrosis) and to the ...
openaire +2 more sources
New England Journal of Medicine, 1971
Fancy phrases readily capture headlines, and fancy names stick better. The field of medicine is no exception. Confusing and poorly understood syndromes frequently hide behind the names of people who describe them or suffer from them. Occasionally, the diseases acquire mysterious names, and then everybody seems to remember them better. "Histiocytosis X"
openaire +2 more sources
Fancy phrases readily capture headlines, and fancy names stick better. The field of medicine is no exception. Confusing and poorly understood syndromes frequently hide behind the names of people who describe them or suffer from them. Occasionally, the diseases acquire mysterious names, and then everybody seems to remember them better. "Histiocytosis X"
openaire +2 more sources